8-K: Celularity Regains Compliance with Nasdaq Listing Rule After Paying Past Due Fees

Celularity Inc. has been notified by Nasdaq that it has regained compliance with Listing Rule 5250(f) after paying its past due fee balance of $70,000.

Summary

• Celularity Inc. received notification from Nasdaq on April 30, 2025, that it has regained compliance with Listing Rule 5250(f).
• This compliance was achieved after Celularity paid its past due fee balance of $70,000.
• The matter is now closed.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has resolved a compliance issue, removing a potential risk factor.

Positives

• Celularity has resolved its non-compliance issue with Nasdaq.
• The company's stock and warrants will continue to be listed on the Nasdaq Stock Market LLC.

Risks

• Failure to maintain compliance with Nasdaq listing rules in the future could result in delisting.

Future Outlook

The announcement does not contain any specific forward-looking statements or guidance.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc.

Industry Context

Maintaining compliance with listing rules is crucial for companies to retain investor confidence and access to capital markets. Failure to do so can lead to decreased stock value and potential delisting.

Comparison to Industry Standards

• Nasdaq listing requirements are standard for companies listed on the exchange.
• Many companies face challenges in maintaining compliance with these rules, especially smaller or growth-stage companies.

Stakeholder Impact

• Shareholders: Regaining compliance with Nasdaq listing rules can positively impact shareholder confidence.
• Employees: Continued listing on Nasdaq ensures the company's stability and future prospects.

Key Dates

Keywords

Nasdaq, compliance, listing rule, Celularity, fees, CELU, CELUW